Johnson & Johnson submits additional data to FDA on psoriatic arthritis
The submission is supported by results from the Phase 3b APEX study
The submission is supported by results from the Phase 3b APEX study
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity
Fermenta now becomes one of the only two companies globally to hold a CEP for this variant of Vitamin D3
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
For patients with resectable early-stage gastric and gastroesophageal junction cancers
The Genexus platform enables Next-Generation Sequencing with significantly faster turnaround times
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
Subscribe To Our Newsletter & Stay Updated